About Dharmacon
Dharmacon is a company based in Lafayette (United States) founded in 1995 was acquired by Horizon Discovery in July 2017. Dharmacon has raised $5.7 million across 1 funding round from investors including Horizon Discovery, Boulder Ventures and Telegraph Hill Partners. Dharmacon offers products and services including CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Transfection Reagents. Dharmacon operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Lafayette, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Revvity Discovery Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.7 M (USD)
in 1 rounds
-
Latest Funding Round
$5.7 M (USD), Series A
Aug 23, 2002
-
Investors
Horizon Discovery
& 2 more
-
Employee Count
Not available
-
Acquired by
Horizon Discovery
(Jul 19, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dharmacon
Dharmacon offers a comprehensive portfolio of products and services, including CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Transfection Reagents.
Reagents for precise genome modification in research.
Tools for RNA interference to silence gene expression.
Tailored RNA and DNA for specific research applications.
Products to deliver nucleic acids into cells efficiently.
Funding Insights of Dharmacon
Dharmacon has successfully raised a total of $5.7M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.7 million completed in August 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dharmacon
Dharmacon has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Horizon Discovery, Boulder Ventures and Telegraph Hill Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is offered by Boulder Ventures for innovative companies.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science, medical device and healthcare companies
|
Locked | Locked | Locked | |
|
Genetically modified cell lines are developed using AAV gene-editing platform.
|
Locked | Locked | Locked |
Investor details for Dharmacon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dharmacon
Investment portfolio details for Dharmacon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dharmacon
Detailed financials for Dharmacon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dharmacon Comparisons
Peer comparison for Dharmacon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dharmacon
Dharmacon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Dharmacon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dharmacon
Complete news archive for Dharmacon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dharmacon
Dharmacon was founded in 1995 and raised its 1st funding round 7 years after it was founded.
Dharmacon is headquartered in Lafayette, United States. It is registered at Lafayette, Louisiana, United States.
Dharmacon is a funded company, having raised a total of $5.7M across 1 funding round to date.
Dharmacon was founded in 1995 in Lafayette, United States, and operates within the biotechnology sector. Technology for RNA oligonucleotide synthesis is offered, including the 2-ACE RNA method for high-quality synthetic RNA. RNAi-related products and siRNA design services are provided, along with CRISPR Cas9 gene editing tools, custom RNA synthesis, and functional genomic screening capabilities to support various research needs.
Dharmacon's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Dharmacon offers CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Transfection Reagents.
Dharmacon has 3 investors. Key investors include Horizon Discovery, Boulder Ventures, and Telegraph Hill Partners.